{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-23-003943","form_type":"8-K","ticker":"CMPX","cik":"0001738021","company_name":"Compass Therapeutics, Inc.","filed_at":"2023-06-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.306073+00:00","generated_at":"2026-06-14T00:23:49.749455+00:00","sec_items":["5.07"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"confidence":"high","headline":"Compass Therapeutics announces results of 2023 annual meeting of stockholders","bullets":["Elected Thomas J Schuetz and Richard S Lindahl as Class III directors for three-year terms.","Schuetz: 67,240,784 for, 17,368,756 withheld; Lindahl: 84,596,658 for, 12,882 withheld.","Ratified CohnReznick LLP as independent auditor for 2023: 96,574,239 for, 130,740 against, 24,542 abstained.","Broker non-votes: 12,119,981 on director election; none on auditor ratification."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-23-003943","json":"https://secwatch.observer/filing/0001171843-23-003943.json","markdown":"https://secwatch.observer/filing/0001171843-23-003943.md","text":"https://secwatch.observer/filing/0001171843-23-003943.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1738021/000117184323003943/0001171843-23-003943-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1738021/000117184323003943/f8k_061523.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T00:23:49.749455+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"66590ca642f4857bff01b942dd30e4ff9a2a09f9","claim":"Compass Therapeutics, Inc. shareholders approved Election of Class III Directors at the 2023-06-15 meeting.","evidence_excerpt":"Proposal No. 1. Election of Directors. The stockholders elected the two Class III nominees for director to serve until the Company’s 2026 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified, by the votes set forth in the table below: Broker Non- Name For Withheld votes Thomas J Schuetz MD PHD 67,240,784 17,368,756 12,119,981 Richard S Lindahl MBA 84,596,658 12,882 12,119,981","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1738021/000117184323003943/0001171843-23-003943-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-06-15"}],"fact_type":"shareholder_vote"},{"claim_id":"77f12c4ecd5a6e36b449db1a16041ff480309c8b","claim":"Compass Therapeutics, Inc. shareholders approved Ratification of Appointment of Independent Registered Public Accounting Firm at the 2023-06-15 meeting.","evidence_excerpt":"Proposal No. 2. Ratification of Appointment of Independent Registered Public Accounting Firm. The stockholders ratified the appointment of CohnReznick, LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2023, by the votes set forth in the table below: Broker Non- For Against Abstained votes 96,574,239 130,740 24,542 0","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1738021/000117184323003943/0001171843-23-003943-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-06-15"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}